Once daily controlled release matrix tablet of Prochlorperazine maleate: Influence of Ethocel^® and/or Methocel^® on in vitro drug release and bioavailability

References

• Tramèr MR, Walder B. (1999). Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesth Analg, 88:1354–1361.
   PubMed Web of Science ®Google Scholar
• Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S et al. (1996). Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther, 18:778–788.
   PubMed Web of Science ®Google Scholar
• Williams PI, Smith M. (1999). An assessment of prochlorperazine buccal for the prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy. Eur J Anaesthesiol, 16:638–645.
   PubMed Web of Science ®Google Scholar
• Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. (2004). Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med, 43:256–262.
   PubMed Web of Science ®Google Scholar
• Miller MA, Levsky ME, Enslow W, Rosin A. (2009). Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med, 27:160–164.
   PubMed Web of Science ®Google Scholar
• Olver IN, Wolf M, Laidlaw C, Bishop JF, Cooper IA, Matthews J et al. (1992). A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer, 28A:1798–1802.
   PubMed Web of Science ®Google Scholar
• Fallon R, Fraser C, Moriarty K. (2007). Recommended management of nausea and vomiting. Prescriber, 18:50–61.
   Google Scholar
• Huang YT, Tsai TR, Cheng CJ, Cham TM, Lai TF, Chuo WH. (2007). Formulation design of an HPMC-based sustained release tablet for pyridostigmine bromide as a highly hygroscopic model drug and its in vivo/in vitro dissolution properties. Drug Dev Ind Pharm, 33:1183–1191.
   PubMed Web of Science ®Google Scholar
• Shah SN, Asghar S, Choudhry MA, Akash MS, ur Rehman N, Baksh S. (2009). Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology. Drug Dev Ind Pharm, 35:1470–1478.
   PubMed Web of Science ®Google Scholar
• Badshah A, Subhan F, Rauf K. (2010). Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability. AAPS Pharmscitech, 11:1397–1404.
   PubMed Web of Science ®Google Scholar
• Kranz H, Wagner T. (2006). Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. Eur J Pharm Biopharm, 62:70–76.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Dashevsky A, Bodmeier R. (2000). pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. J Control Release, 67:101–110.
   PubMed Web of Science ®Google Scholar
• Gohel MC, Parikh RK, Nagori SA, Jena DG. (2009). Fabrication of modified release tablet formulation of metoprolol succinate using hydroxypropyl methylcellulose and xanthan gum. AAPS Pharmscitech, 10:62–68.
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Rajabi-Siahboomi AR. (2009). Applications of complementary polymers in HPMC hydrophilic extended release matrices. Drug Deliv Tech, 9:20–27.
   Google Scholar
• Chaibva FA, Khamanga SM, Walker RB. (2010). Swelling, erosion and drug release characteristics of salbutamol sulfate from hydroxypropyl methylcellulose-based matrix tablets. Drug Dev Ind Pharm, 36:1497–1510.
   PubMed Web of Science ®Google Scholar
• Levina M, Vuong H, Rajabi-Siahboomi AR. (2007). The influence of hydro-alcoholic media on hypromellose matrix systems. Drug Dev Ind Pharm, 33:1125–1134.
   PubMed Web of Science ®Google Scholar
• Agrawal AM, Neau SH, Bonate PL. (2003). Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release. AAPS Pharmsci, 5:E13.
   PubMedGoogle Scholar
• Khan GM, Meidan VM. (2007). Drug release kinetics from tablet matrices based upon ethylcellulose ether-derivatives: a comparison between different formulations. Drug Dev Ind Pharm, 33:627–639.
   PubMed Web of Science ®Google Scholar
• Tatavarti AS, Hoag SW. (2006). Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices. J Pharm Sci, 95:1459–1468.
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Rajabi-Siahboomi AR. (2008). Modulation of drug release from hydrophilic matrices. Pharm Technol Europe. Accessed at http://www.ptemag.com/. 73.
   Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15:25–35.
   Web of Science ®Google Scholar
• Ritger PL, Peppas NA. (1987). A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release, 5:23–36.
   Google Scholar
• Ritger PL, Peppas NA. (1987) A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release, 5:37–42.
   Google Scholar
• FDA. (1997). Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. Rockville, MD: CDER.
   Google Scholar
• Gohel MC, Panchal MK. (2002). Novel use of similarity factors f2 and Sd for the development of diltiazem HCl modified-release tablets using a 3(2) factorial design. Drug Dev Ind Pharm, 28:77–87.
   PubMed Web of Science ®Google Scholar
• Shah VP, Tsong Y, Sathe P, Liu JP. (1998). In vitro dissolution profile comparison–statistics and analysis of the similarity factor, f2. Pharm Res, 15:889–896.
   PubMed Web of Science ®Google Scholar
• Malkawi AH, Al-Ghananeem AM, Crooks PA. (2008). Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery. AAPS J, 10:261–267.
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Ridhurkar DN, Pandit JK. (2010). In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet. AAPS Pharmscitech, 11:294–303.
   PubMed Web of Science ®Google Scholar
• Fowler A, Taylor W, Bateman DN. (1986). Plasma prochlorperazine assay by high-performance liquid chromatography–electrochemistry. J Chromatogr, 380:202–205.
   PubMed Web of Science ®Google Scholar
• Shargel L, Yu A. (1999). Bioavailability and bioequivalence. In Applied Biopharmaceutics and Pharmacokinetics, New york: McGraw-Hill, 247–279.
   Google Scholar
• Wagner JG, Nelson E. (1964). Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci, 53:1392–1403.
   PubMed Web of Science ®Google Scholar
• Nur AO, Zhang JS. (2000). Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm, 26:965–969.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. (2003). Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci, 18:37–45.
   PubMed Web of Science ®Google Scholar
• FDA. (2001). Guidance for industry. Bioanalytical method validation. Rockville, MD: CDER.
   Google Scholar
• Shabir GA. (2003). Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr a, 987:57–66.
   PubMed Web of Science ®Google Scholar
• Chowhan Z. (1980) Role of binders in moisture induced hardness increase in compressed tablets and its effect on in vitro disintegration and dissolution. J Pharmaceut Sci, 69:1–4.
   PubMed Web of Science ®Google Scholar
• Badshah A, Subhan F, Rauf K, Irfan Bukhari N, Shah K, Khan S, et al. (2011). Development of controlled-release matrix tablet of risperidone: influence of methocel®-and ethocel®-based novel polymeric blend on in vitro drug release and bioavailability. AAPS PharmSciTech, 1–9 (in press).
   Google Scholar
• Desai RP, Neau SH, Pather SI, Johnston TP. (2001). Fine-Particle ethylcellulose as a tablet binder in direct compression, immediate-release tablets. Drug Dev Ind Pharm, 27:633–641.
   PubMed Web of Science ®Google Scholar
• Bettini R, Catellani PL, Santi P, Massimo G, Peppas NA, Colombo P. (2001). Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. J Control Release, 70:383–391.
   PubMed Web of Science ®Google Scholar
• Howard J, Timmins P. (1988). Controlled release formulation. US Patent 4,792,452.
   Google Scholar
• Rekhi GS, Nellore RV, Hussain AS, Tillman LG, Malinowski HJ, Augsburger LL. (1999). Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. J Control Release, 59:327–342.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ et al. (2000). Bioanalytical method validation–a revisit with a decade of progress. Pharm Res, 17:1551–1557.
   PubMedGoogle Scholar
• Tanaka E, Nakamura T, Terada M, Shinozuka T, Hashimoto C, Kurihara K et al. (2007). Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 854:116–120.
   PubMed Web of Science ®Google Scholar